



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

GlaxoSmithKline
GLOBAL PATENTS -US, UW2220
P. O. BOX 1539
KING OF PRUSSIA PA 19406-0939

MAILED
JUN 08 2010
OFFICE OF PETITIONS

In re Application of :
Hasegawa, et al. : DECISION ON PETITION
Application No. 10/535,690 :
Filed: April 10, 2006 :
Atty. Dkt. No.: TC00001 :

This is a decision on the petition under 37 CFR 1.137(b), filed March 3, 2010.

The petition is **GRANTED**.

This application became abandoned January 22, 2010 for failure to timely reply to the Notice of Allowance and Issue Fee Due (Notice) mailed October 21, 2009. The Notice set a three (3) month statutory period of time for reply. Notice of Abandonment was mailed February 5, 2010.

A grantable petition under 37 CFR 1.137(b) must be accompanied by: (1) the required reply, unless previously filed; (2) the petition fee as set forth in 37 CFR 1.17(m); (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137(b) was unintentional; and (4) any terminal disclaimer (and fee as set forth in 37 CFR 1.20(d)) required by 37 CFR 1.137(d). Where there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137 was unintentional, the Director may require additional information. See MPEP 711.03(c)(II)(C) and (D).

The instant petition has been carefully reviewed and found in compliance with the requirements set forth above.

The file does not indicate a change of address has been submitted, although the address given on the petition differs from the address of record. If appropriate, a change of address should be filed in accordance with MPEP 601.03. A courtesy copy of this decision is being mailed to the address given on the petition; however, the Office will mail all future correspondence solely to the address of record.

In view thereof, this application is being forwarded to the Office of Data Management for further processing.

Telephone inquiries concerning this matter may be directed to the undersigned at (571) 272-3205.

/ALESIA M. BROWN/

Alesia M. Brown
Petitions Attorney
Office of Petitions

CC: WAYNE DUSTMAN
GlaxoSmithKline CORP
709 Swedeland Rd
P O Box 1539
King Of Prussia, PA 19406